Zobrazeno 1 - 10
of 109
pro vyhledávání: '"E M, VAUGHAN WILLIAMS"'
Autor:
E M, VAUGHAN WILLIAMS
Publikováno v:
The Journal of physiology. 105(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::54090296e992d99b2131b047035a425d
https://pubmed.ncbi.nlm.nih.gov/20283158
https://pubmed.ncbi.nlm.nih.gov/20283158
Autor:
E. M. Vaughan Williams
Publikováno v:
Journal of Cardiovascular Pharmacology. 20:1-7
The division of class I antiarrhythmic agents (sodium-channel blockers) into Ia, Ib, and Ic subgroups was based on clinical observations. Lidocaine, mexiletine, and tocainide (Ib) did not alter the QRS or H-V interval in sinus rhythm, but prolonged e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa8c2a5453b1327dc77eff50d1511a19
https://doi.org/10.1097/00005344-199212031-00001
https://doi.org/10.1097/00005344-199212031-00001
Autor:
E. M. Vaughan Williams
Publikováno v:
The Journal of Clinical Pharmacology. 32:964-977
Classification of antiarrhythmic actions is reviewed in the context of the results of the Cardiac Arrhythmia Suppression Trials, CAST 1 and 2. Six criticisms of the classification recently published (The Sicilian Gambit) are discussed in detail. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42e901d4936a0086b07da85d184a93bb
https://doi.org/10.1002/j.1552-4604.1992.tb03797.x
https://doi.org/10.1002/j.1552-4604.1992.tb03797.x
Autor:
E M, Vaughan Williams
Publikováno v:
Journal of cardiovascular pharmacology. 20
The division of class I antiarrhythmic agents (sodium-channel blockers) into Ia, Ib, and Ic subgroups was based on clinical observations. Lidocaine, mexiletine, and tocainide (Ib) did not alter the QRS or H-V interval in sinus rhythm, but prolonged e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a308729d6cc084548016d8a5374ad168
https://pubmed.ncbi.nlm.nih.gov/1279301
https://pubmed.ncbi.nlm.nih.gov/1279301
Autor:
E M, Vaughan Williams
Publikováno v:
Cardiovascular Research. 45:41-42
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91ab1ffd834d07ba3ec4e29a6fffccf9
https://doi.org/10.1016/s0008-6363(99)00305-3
https://doi.org/10.1016/s0008-6363(99)00305-3
Autor:
E. M. Vaughan Williams
Publikováno v:
Journal of clinical pharmacology. 31(3)
The subdivisiion of class 1 antiarrhythmic agents into groups a, b, and c was originally based on clinical electrophysiologic findings. Class 1b compounds did not alter QRS or HV interval in sinus rhythm, but the compounds did lengthen ERP in spite o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bc3a45f32324b75ec2c3d1797113911
https://pubmed.ncbi.nlm.nih.gov/2019662
https://pubmed.ncbi.nlm.nih.gov/2019662
Autor:
E. M. Vaughan Williams
Publikováno v:
Journal of clinical pharmacology. 31(2)
The Cardiac Antiarrhythmic Suppression Trial (CAST) showed flecainide and encainide induced excess mortality compared with placebo. Labeling drugs as Class 1C is based on clinical observations, comprising measurements of the electrocardiographic para
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a604557fef2b54dbeb72fdff574220a
https://pubmed.ncbi.nlm.nih.gov/1901322
https://pubmed.ncbi.nlm.nih.gov/1901322
Autor:
E. M. Vaughan Williams
Publikováno v:
Cardiovascular Research. 29:292-292
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1edc1e22cb1f3ee271705e5e4e493480
https://doi.org/10.1016/s0008-6363(95)90017-9
https://doi.org/10.1016/s0008-6363(95)90017-9